Riluzole

Structural formula
General
Non-proprietary name	Riluzole
other names	6- (trifluoromethoxy) -1,3-benzothiazol-2-amine ( IUPAC )
Molecular formula	C 8 H 5 F 3 N 2 OS
Brief description	white solid
External identifiers / databases
EC number	605-724-6
ECHA InfoCard	100.124.754
PubChem	5070
ChemSpider	4892
DrugBank	DB00740
Wikidata	Q415744
Drug information
ATC code	N07 XX02
properties
Molar mass	234.20 g · mol -1
solubility	> 25 g l −1 in DMSO
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 301
	P: 301 + 310
Toxicological data	67 mg kg −1 ( LD 50 , mouse , oral )
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Riluzole (trade name Rilutek ^® ) is a drug that is used to treat amyotrophic lateral sclerosis (ALS). It extends the patient's survival time in this disease.

The chemical substance belongs to the group of benzothiazoles .

Use in psychiatry

Several recent case studies have shown that riluzole could be used successfully, especially in anxiety disorders.

A form of riluzole developed for sublingual use, known by the code name BHV-0223, is currently being developed by Biohaven Pharmaceuticals for the treatment of generalized anxiety and mood disorders.

Pharmacological properties

Riluzole is a sodium channel blocker and attenuates the effects of the neurotransmitter glutamate .

Individual evidence

↑ ^a ^b ^c ^d ^e Riluzole data sheet from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).

↑ Scientific discussion for the approval of RILUTEK ( en , PDF; 133 kB) European Medicines Agency . P. 12. January 1, 2004. Retrieved August 10, 2010.

↑ Paul Grant, Jane Y. Song, Susan E. Swedo: Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder . In: Journal of Child and Adolescent Psychopharmacology . tape 20 , no. 4 , August 2010, p. 309-315 , doi : 10.1089 / cap.2010.0009 , PMID 20807069 , PMC 2958461 (free full text).

↑ Riluzole sublingual - Biohaven Pharmaceutical - AdisInsight. Retrieved March 19, 2019 .

^ Elaine Harris: Industry update: the latest developments in therapeutic delivery . In: Therapeutic Delivery . 6, No. 6, 2015, pp. 647-652. doi : 10.4155 / tde.15.44 .

[sigma-1] Riluzole data sheet from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).

[ema-2] Scientific discussion for the approval of RILUTEK ( en , PDF; 133 kB) European Medicines Agency . P. 12. January 1, 2004. Retrieved August 10, 2010.

[3] Paul Grant, Jane Y. Song, Susan E. Swedo: Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder . In: Journal of Child and Adolescent Psychopharmacology . tape 20 , no. 4 , August 2010, p. 309-315 , doi : 10.1089 / cap.2010.0009 , PMID 20807069 , PMC 2958461 (free full text).

[4] Riluzole sublingual - Biohaven Pharmaceutical - AdisInsight. Retrieved March 19, 2019 .

[5] Elaine Harris: Industry update: the latest developments in therapeutic delivery . In: Therapeutic Delivery . 6, No. 6, 2015, pp. 647-652. doi : 10.4155 / tde.15.44 .